Research progress of rare lung cancers

Liu Yining,Cui Jiuwei

DOI: https://doi.org/10.12151/JMCM.2022.03-02

2022-01-01

Abstract:Lung cancer has the highest global mortality among all malignancies, according to the report on cancer incidence in China in 2016, the number of lung cancer patients and deaths was 828 000 and 657 000 respectively, at present, the understandings and researches of rare lung cancers are still limited. Increasingly, subtypes of common cancers are classified as "rare" based on diagnostic criteria of molecular markers, which rely on more accurate gene tests. Next-generation sequencing is an effective means of discovering gene targets of rare cancers. Comprehensive genome profiling can detect rare mutated genes or atypical variants in the context of specific tumor types, providing information for new therapeutic strategies and improving the prognosis of patients with rare cancers. Patient-derived tumor models are a key tool in cancer research to investigate gene functions, screen for antitumor effects of new drugs, and validate cancer biology and therapeutics, especially for rare cancers. Given the growing number of drugs targeting genomic alterations in tumor-specific contexts, the exploration of clinical trials is helping to broaden the potential of genome-driven oncology applications. This text reviews the progress in molecular detection, clinical trials, model studies and therapeutic applications of rare lung cancers.